Keyword: American College of Cardiology
Novartis' canakinumab, a rare disease med it's studying for the heart, cut CV risks in patients with diabetes and chronic kidney disease, data shows.
Johnson & Johnson is trumpeting more Invokana outcomes data to support its approval to reduce cardiovascular risks.
When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
With a new study in patients with peripheral artery disease, Johnson & Johnson has once again bolstered its case for another Xarelto approval.
With some new Plavix-matching data, AstraZeneca may have just found a new niche for its blood thinner Brilinta.
Sanofi and Regeneron presented Odyssey outcomes data for Praluent at ACC 2018 Saturday.
The PCSK9 cholesterol drugs got top billing at the American College of Cardiology meeting this year, but that doesn’t mean other studies didn’t rate.
Novartis' slow-starting heart failure med Entresto reduced patients' blood sugar levels more than a head-to-head rival did, a new analysis shows.